clinical trial · NCT00681343
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
University of Miami·phase4·completed·n = 38
Living-Donor Kidney TransplantThymoglobulinCampath-1HDaclizumab
brief summary
To observe in a randomized prospective pilot study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with our standard treatment protocol of Zenapax® and maintenance immunosuppression
started
Sep 1, 2002
primary completion
Oct 1, 2006
completion
Oct 1, 2007
last updated
Sep 14, 2023
official title
Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Living Donor Renal Transplantation - A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol